250 related articles for article (PubMed ID: 28700622)
1. Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms.
Dobrovolny HM; Beauchemin CAA
PLoS One; 2017; 12(7):e0180582. PubMed ID: 28700622
[TBL] [Abstract][Full Text] [Related]
2. Intermittent treatment of severe influenza.
Deecke L; Dobrovolny HM
J Theor Biol; 2018 Apr; 442():129-138. PubMed ID: 29355540
[TBL] [Abstract][Full Text] [Related]
3. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy.
Wu JT; Leung GM; Lipsitch M; Cooper BS; Riley S
PLoS Med; 2009 May; 6(5):e1000085. PubMed ID: 19440354
[TBL] [Abstract][Full Text] [Related]
4. Influenza virus resistance to antiviral therapy.
van der Vries E; Schutten M; Fraaij P; Boucher C; Osterhaus A
Adv Pharmacol; 2013; 67():217-46. PubMed ID: 23886002
[TBL] [Abstract][Full Text] [Related]
5. Incidence of antiviral drug resistance markers among human influenza A viruses in the Eastern Mediterranean Region, 2005-2016.
Moasser E; Moasser A; Zaraket H
Infect Genet Evol; 2019 Jan; 67():60-66. PubMed ID: 30389548
[TBL] [Abstract][Full Text] [Related]
6. Antivirals and resistance: influenza virus.
Ison MG
Curr Opin Virol; 2011 Dec; 1(6):563-73. PubMed ID: 22440914
[TBL] [Abstract][Full Text] [Related]
7. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
Nguyen HT; Fry AM; Gubareva LV
Antivir Ther; 2012; 17(1 Pt B):159-73. PubMed ID: 22311680
[TBL] [Abstract][Full Text] [Related]
8. Antiviral resistance and the control of pandemic influenza.
Lipsitch M; Cohen T; Murray M; Levin BR
PLoS Med; 2007 Jan; 4(1):e15. PubMed ID: 17253900
[TBL] [Abstract][Full Text] [Related]
9. Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains.
Shin WJ; Seong BL
Expert Opin Drug Discov; 2019 Feb; 14(2):153-168. PubMed ID: 30585088
[TBL] [Abstract][Full Text] [Related]
10. Combination antiviral therapy for influenza: predictions from modeling of human infections.
Perelson AS; Rong L; Hayden FG
J Infect Dis; 2012 Jun; 205(11):1642-5. PubMed ID: 22448006
[TBL] [Abstract][Full Text] [Related]
11. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.
Hurt AC; Ho HT; Barr I
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):795-805. PubMed ID: 17140356
[TBL] [Abstract][Full Text] [Related]
12. Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread.
Handel A; Longini IM; Antia R
PLoS Comput Biol; 2007 Dec; 3(12):e240. PubMed ID: 18069885
[TBL] [Abstract][Full Text] [Related]
13. Fitness of neuraminidase inhibitor-resistant influenza A viruses.
Baranovich T; Webster RG; Govorkova EA
Curr Opin Virol; 2011 Dec; 1(6):574-81. PubMed ID: 22440915
[TBL] [Abstract][Full Text] [Related]
14. Antivirals and influenza: frequency of resistance.
Monto AS
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S110-2. PubMed ID: 18820569
[TBL] [Abstract][Full Text] [Related]
15. Predicting Permissive Mutations That Improve the Fitness of A(H1N1)pdm09 Viruses Bearing the H275Y Neuraminidase Substitution.
Farrukee R; Gunalan V; Maurer-Stroh S; Reading PC; Hurt AC
J Virol; 2022 Aug; 96(15):e0091822. PubMed ID: 35867563
[TBL] [Abstract][Full Text] [Related]
16. Influenza drug resistance.
Pizzorno A; Abed Y; Boivin G
Semin Respir Crit Care Med; 2011 Aug; 32(4):409-22. PubMed ID: 21858746
[TBL] [Abstract][Full Text] [Related]
17. Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.
Ruangrung K; Suptawiwat O; Maneechotesuwan K; Boonarkart C; Chakritbudsabong W; Assawabhumi J; Bhattarakosol P; Uiprasertkul M; Puthavathana P; Wiriyarat W; Jongkaewwattana A; Auewarakul P
J Virol; 2016 May; 90(9):4637-4646. PubMed ID: 26912622
[TBL] [Abstract][Full Text] [Related]
18. Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment.
Liu Q; Ma J; Strayer DR; Mitchell WM; Carter WA; Ma W; Richt JA
Expert Rev Anti Infect Ther; 2014 Feb; 12(2):165-9. PubMed ID: 24350808
[TBL] [Abstract][Full Text] [Related]
19. An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
Hu Y; Musharrafieh R; Ma C; Zhang J; Smee DF; DeGrado WF; Wang J
Antiviral Res; 2017 Apr; 140():45-54. PubMed ID: 28087313
[TBL] [Abstract][Full Text] [Related]
20. Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
Tilmanis D; Koszalka P; Barr IG; Rossignol JF; Mifsud E; Hurt AC
Antiviral Res; 2020 Aug; 180():104851. PubMed ID: 32544408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
